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Background: We evaluated whether immune activation (IA) and microbial translocation (MT) might play a role in
accelerating liver disease progression in HIV-HBV/HCV co-infected patients.
Methods: ART-naïve HIV/viral hepatitis co-infected patients from Icona with a CD4 cell count >200/μl and with a
known date of prior HIV neg/pos tests and ≥1 plasma sample stored were included in the study. Plasma MT
(LPS, sCD14) and IA (IL-6,TNFα) were measured using ELISA while activated CD8 + CD38 + HLA-DR + were measured
by flow cytometry, with one measurement being performed for all patients and two measurements for a smaller
group of subjects. The association between these biomarkers and the time to i) a single ALT >200 IU/l and ii) a
Fib-4 >1.45 was also investigated. A standard survival analysis with robust standard errors was used for all
evaluations. Follow-up was censored at patients’ last clinical follow-up.
Results: We studied 127 HIV-infected hepatitis viruses co-infected patients (118 HCV, 9 HBV). Overall median (IQR)
CD4, VL, age were 596/μl (208–1303), 3.8 log10cp/mL (3–4.3), 34 years (22–56). While heightened TNF-α was
associated with a 13-fold increased risk of Fib-4 > 1.45 (RH 13.05, 95% CI 2.43-70; p = 0.003), markers of MT did not
show an association with liver illness. Interestingly, higher sCD14 was associated with a decreased risk of Fib-4 > 1.45,
independently of other biomarkers considered (RH 0.20, 95% CI 0.04-0,9; p = 0.04).
Conclusions: In HIV/hepatitis virus co-infected ART-naive patients, higher TNF-α plasma levels were associated with a
13-fold increase in the risk of progression to a Fib-4 >1.45, suggesting that the pro-inflammatory status in HIV infection
might hasten the course of HCV. In view of the fact that sCD14 may hinder the interaction between LPS and the
phagocyte membrane CD14, we herewith propose a model which aims to demonstrate that high sCD14 levels might
contribute to shelter liver function through the down-regulation of the inflammatory cascade.
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HBV/HCV co-infection with HIV is known to accelerate
liver disease progression, however, the precise mecha-
nisms by which this occurs have yet to be fully elucidated.
Amongst numerous causes, microbial translocation
(MT) from the gut has been shown to substantially con-
tribute to liver disease in several clinical settings such as
alcoholic liver disease, and other enteric processes [1-4].
In chronic HBV and HCV infection, sCD14 levels dif-
ferentiate HBV/HCV-infected subjects with severe liver
fibrosis from those with minimal fibrosis, and are associ-
ated with the risk of failure to respond to anti-HCV
treatment with pegylated-interferon-α/ribavirin, suggest-
ing that the host response to MT might predict the out-
come of the disease [5].
In HIV infection, MT has been linked to immune acti-
vation (IA) [6] and correlates with the clinical outcome
independently of CD4+ counts and HIV RNA levels
[7,8]; thus, a common pathogenic role of MT in fuelling
viral hepatic illness has been hypothesized. Accordingly,
in keeping with these findings, MT has been shown to
accelerate liver disease progression in cohorts of HIV-
infected and HIV uninfected patients [9-11], and hamper
the response to pegylated-interferon-α/ribavirin treat-
ment in HCV/HIV co-infected patients [12]. Most re-
cently, in a retrospective case–control study of HIV + and
HIV- Ugandan subjects with detectable liver stiffness/
cirrhosis in the absence of HCV infection, Redd et al.
demonstrated a significant association between monocyte
activation and liver disease only in HIV-infected patients,
that appeared however unrelated to MT [13].
Given these premises, we investigated whether MT
and IA markers might be able to predict the progression
of hepatic disease in a cohort of HIV-HBV/HCV co-
infected patients.
Methods
Study population
This is a nested analysis within a main study in the
ICONA Cohort which investigated the association be-
tween biomarkers of MT and IA and HIV progression
[7]. The study was approved by the Ethical Committee
of all the Centers participating to the ICONA Founda-
tion Study (see ackowledgments). All patients signed
written consent for use of biological material. Details of
the ICONA Foundation Study cohort study and data
collection have been previously reported [7].
Briefly, the main study mentioned above was conducted
in a subgroup of patients enrolled in the ICONA Founda-
tion Study with a documented date of last HIV-negative
and first HIV-positive test, at least one plasma stored
while antiretroviral therapy (ART)-naive and a CD4+ cell
count greater than 200 cells/l and ALT < 200 IU/L at the
date of the stored plasma considered for this analysis. If apatient had more than one sample satisfying these criteria,
the less recent sample was used. For some patients 2 sam-
ples were used, this less recent sample and another sample
collected about 1 year later. In this nested analysis only
patients who were tested positive for HCV antibodies or
HBV antigens were included.
Assessment of liver fibrosis
The non-invasive marker of liver fibrosis Fib-4 was cal-
culated as per the recommended formula: age (years) ×
AST [U/l]/(platelets [109/l] × (ALT [U/l])1/2) [14]. For
the purpose of our research we decided to use as end-
point a Fib-4 value >1.45, based on literature data show-
ing that a threshold value <1.45 has a negative predictive
value for the exclusion of extensive fibrosis (F4-F6 of the
Ishak classification) of 90%, and a threshold value >3.25
has a positive predictive value for the diagnosis of ex-
tended fibrosis of 65% [14,15]. We defined as events all
the patients with a Fib-4 value >1.45 that was confirmed
by another value >1.45.
Assessment of immune activation
Commercially available ELISA kits were used to quan-
tify plasma levels of sCD14, IL-6, and TNF-α (R&D
Systems Europe, Abingdon, United Kingdom). The as-
says were performed in duplicate according to manu-
facturer’s instructions. In a subset of patients with an
available frozen cell sample stored in viable conditions,
surface phenotypes were evaluated on thawed PBMCs
by flow cytometry (FACS Sort Becton-Dickinson, San
Josè, California, USA) using directly labeled antibodies
(fluorescein isothiocyanate [FITC], phycoerytrin [PE],
and Peridinin-chlorophyll-protein complex cyanin 5.5
[PerCP Cy5.5]). We determined CD8+ T-lymphocyte
activation by measuring the expression of HLA-DR and
CD38. The following combination was used: CD8/CD38/
HLA-DR (CD38-PE, HLA-DR-FITC CD8-PerCP Cy5.5,
Becton Dickinson, San Josè, CA, USA). All biomarkers
were measured in a central laboratory and all technicians
were blinded to patients’ disease progression status.
Plasma concentrations of LPS were determined with
a commercial LAL kit (Kinetic-QCL; Bio Whittaker,
Walkersville, MD, USA) for the quantitative determin-
ation of LPS using a known endotoxin standard as a
reference (E. coli O55:B5 endotoxin). Plasma samples
were diluted with endotoxin-free water and then heated
to 90°C for 15 min to inactivate plasma proteins. The
assay was carried out according to the protocol recom-
mended by the manufacturer.
Statistical analysis
The main characteristics of the study population of co-
infected individuals have been described. Kaplan-Meier
plots were used to investigate, the association of MT
Table 1 Baseline characteristic of HIV-HBV/HCV study
population at the date of stored plasma
Characteristics N = 127
Gender, n(%)
Female 45 (35.4%)
Age, years
Median (range) 34 (22, 56)
Mode of HIV transmission, n (%)
Homosexual contacts 17 (13.4%)
Heterosexual contacts 20 (15.7%)
IDU 87 (68.5%)
Other/unknown 3 (2.4%)
Viral load, log10 copies/mL
Median (IQR) 3.8 (3.0, 4.3)
CD4 count, cells/mmc
Median (range) 596 (208, 1303)
Hepatitis co-infection, n (%)
HBV+/HCV- 9 (7.1%)
HCV+/HBV- 118 (92.9%)
Time from HIV seroconversion, years
Median (range) 5 (0, 25)
Calendar year of sample
Median (range) 1998 (1997, 2008)
Biomarkers
CD8CD38 + DR+, % (n = 120)
Median (IQR) 45.0 (25.5, 54.9)
IL-6, pg/ml (n = 279)
Median (IQR) 1.1 (0.6, 2.1)
LPS, pg/ml (n = 212)
Median (IQR) 126.2 (75.0, 211.6)
sCD14, mg/ml (n = 294)
Median (IQR) 3.6 (2.0, 5.6)
TNF-alfa, pg/ml (n = 286)
Median (IQR) 2.3 (1.7, 3.4)
ALT, IU/l (n = 360)
Median (IQR) 40.0 (23.0, 63.0)
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ALT >200 IU/l, ii) time to ≥2 consecutive observations
of Fib-4 >1.45. Follow-up was censored at time of last
clinical follow-up.. Moreover, all patients included in
the analysis had a Fib-score <1.45 at baseline and none
of them developed the liver disease or died of liver-
related causes throughout the follow-up period.
An adjusted analysis was performed using a Cox re-
gression model. Patients from whom more than one
sample was obtained contributed to the analysis with
more than one measurement; therefore, robust standard
errors were used to control for non-independence of ep-
isodes coming from the same patient. Biomarkers were
fitted in the models as categorical variables constructed
using the median values observed in the co-infected as
category-defining thresholds. Individuals, for whom no
value could be attained from the sample, were included
as a separate group. Several multivariable models, each
including a single biomarker, were controlled for age,
CD4, viral load (VL), baseline ALT, year of test, and dur-
ation of HIV infection at the date of the test. A further
multivariable model including all biomarkers concomi-
tantly was also fitted.
Results
We analysed the data of 127 patients who had at least
one measure of at least one of the evaluated biomarkers
and contributing 373 measures in the survival analysis.
118 patients were co-infected with hepatitis C, and 9
with hepatitis B virus.
Table 1 shows the baseline characteristics of HIV-HBV/
HCV co-infected patients. HIV-HBV/HCV co-infected pa-
tients displayed median HIV RNA load of 3.8 log10
copies/mL, median ALT levels of 40 IU/l. Sixty-nine
percent of HIV/hepatitis co-infected patients were IDU
and, at baseline, had been infected with HIV for a me-
dian of 5 years. Median activated CD8 + CD38 + HLA-
DR + cells were 45% (IQR 25.5, 54.9), plasma TNF-α was
2.3 pg/mL (IQR 1.7, 3.4) and plasma IL-6 1.1 pg/mL (IQR
0.6, 2.1). Median circulating LPS and sCD14 levels were
126.2 pg/mL (IQR 75.0, 211.6) and 3.6 pg/mL, (IQR 2.0,
5.6), respectively.
122/127 co-infected subjects were included in the time
to ALT and time to Fib-4 elevation analysis according to
TNF-a levels (Figure 1) and sCD14 levels (Figure 2). 5/127
co-infected patients for whom only baseline visit and no
follow-up visit was available were excluded from survival
analysis.
23/122 patients experienced ALT elevation and 18/122
had ≥ 2 consecutive observations of Fib-4 elevation
above the selected threshold, respectively. Patients with
higher circulating TNF-α were more likely to show a
Fib-4 elevation. By 2 years from baseline, 12% (95%
CI:2-22%) of individuals with a baseline TNF-α >2.3 pg/mlexperienced the elevation vs. 5% (95% CI:0-11%) of those
with TNF-α ≤2.3 pg/ml (log rank p = 0.0006).
When considering ALT > 200 IU/L as the measure of
hepatitis disease progression, none of the biomarkers
showed an independent association with the outcome, al-
though subjects with TNF-α >2.3 pg/mL showed a 4-fold
risk of progression in the unadjusted Cox regression
model (vs. people with a value ≤2.3 pg/ml, p = 0.01);
however, this was not confirmed in the adjusted model
(Table 2).
Figure 1 Kaplan-Meier estimates of the risk of ALT elevation (A) and Fib-4 elevation (B) according to TNF-alpha strata. Kaplan-Meier
plots were used to compare the cumulative percent of patients reaching the primary endpoint. The cohort was stratified according to TNF-alpha
plasma levels above or below the median (i.e. 2.3 pg/ml).
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were associated with a >8-fold higher risk of developing
Fib-4 > 1.45 in both the unadjusted (p = 0.005), and ad-
justed analysis (p = 0.003) compared to people with a
value below the median (Table 3).
Most interestingly, in this same model, higher sCD14
levels were also independently associated with a 80% re-
duction in the risk of Fib > 1.45 (p = 0.04) (Table 3).
Indeed, in the univariable analysis, higher levels of
sCD14 were associated with a slightly increased risk of
Fib-4 elevation (Figure 2B). However, the estimated dif-
ference was small: 0.5% increase by 2 years comparingpeople with a sCD14 >3.6 mg/mL vs. ≤3.6 mg/ml using
the Kaplan-Meier approach and a RH = 0.99 per (95%CI
0.36-2.74) using the Cox regression model (Table 3).
However, after controlling for confounding factors the
adjusted RH associated with a sCD14 >3.6 mg/mL was
0.20 (95%CI 0.04-0.9), p = 0.04. The major confounding
factors seem to be the baseline Fib-4 value (higher in
those with sCD14 >3.6 mg/mL, which is also a factor
associated with greater risk of increasing Fib-4) LPS
(inversely correlated with sCD14 and associated with
lower risk of Fib-4 increase) and CD8CD38 +HLA-DR +
values (positively correlated with sCD14 and associated
Figure 2 Kaplan-Meier estimates of the risk of ALT elevation (A) and Fib-4 elevation (B) according to sCD14 strata. Kaplan-Meier plots
were used to compare the cumulative percent of patients reaching the primary endpoint. The cohort was stratified according to sCD14 plasma
levels above or below the median (i.e. 3.6 pg/ml).
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these factors the RH was already modified to a value <1
(RH = 0.46, 95% CI: 0.14-1.52).
Similar results were obtained in a sensitivity analysis
including only HIV/HCV co-infected patients (excluding
HIV/HBV co-infected patients). One hundred and thir-
teen HIV/HCV co-infected individuals were included in
this time to ALT and time to Fib-4 elevation sensitivity
analysis. Interestingly, in the Kaplan-Meier analysis, pa-
tients with higher circulating TNF-a were more likely
to display liver disease progression according to both
endpoints, i.e. ALT > 200 IU/L (log rank p = 0.04) andFib-4 > 1.45 (log rank p = 0.0004). Similar to the main
analysis, compared to people with values below the me-
dian value, those with TNF-α levels higher than the me-
dian showed a >8-fold higher risk of developing Fib-4 >
1.45 in the adjusted analysis (RH 8.10, 95%CI 1.44, 45.68;
p = 0.02); and sCD14 higher than the median was inde-
pendently associated with a reduction in risk of Fib > 1.45
(RH 0.04, 95%CI 0, 0.67; p = 0.03).
Discussion and conclusions
We sought out to investigate whether MT markers
might be able to predict the progression of hepatic
Table 2 Relative hazards of ALT elevation >200 IU/l from fitting a Cox regression model
Crude and adjusted relative hazards of developing ALT>200 IU/l
Biomarker Crude RH (95% CI) p-value Adjusted* RH (95% CI) p-value Adjusted** RH (95% CI) p-value
CD8CD38+DR+, %
<=48% 1.0 1.0 1.0
>48% 0.30 (0.03, 2.93) 0.303 0.17 (0.01, 1.91) 0.150 0.09 (0.01, 1.44) 0.088
not measured 1.24 (0.37, 4.20) 0.726 1.12 (0.32, 3.94) 0.865 0.76 (0.18, 3.27) 0.711
IL-6, pg/ml
<=1.1 1.0 1.0 1.0
>1.1 2.77 (0.98, 7.87) 0.056 1.82 (0.61, 5.43) 0.281 1.56 (0.46, 5.32) 0.481
not measured 2.00 (0.61, 6.57) 0.251 1.79 (0.53, 6.07) 0.351 2.19 (0.18, 27.33) 0.543
LPS, pg/ml
<=126 1.0 1.0 1.0
>126 1.26 (0.44, 3.59) 0.669 0.77 (0.21, 2.83) 0.697 0.39 (0.08, 1.84) 0.235
not measured 0.66 (0.25, 1.78) 0.417 0.67 (0.22, 2.04) 0.478 0.31 (0.08, 1.28) 0.107
sCD14, mg/ml
<=3.6 1.0 1.0 1.0
>3.6 0.82 (0.32, 2.07) 0.669 0.79 (0.29, 2.19) 0.651 0.84 (0.25, 2.82) 0.778
not measured 0.98 (0.33, 2.86) 0.967 1.13 (0.35, 3.59) 0.842 0.80 (0.03, 25.38) 0.900
TNF-alfa, pg/ml
<=2.3 1.0 1.0 1.0
>2.3 4.01 (1.32, 12.21) 0.014 2.14 (0.64, 7.15) 0.217 2.03 (0.57, 7.29) 0.276
not measured 2.48 (0.67, 9.26) 0.175 1.82 (0.46, 7.17) 0.394 1.66 (0.10, 28.78) 0.728
*All models (a separate one for each biomarker) adjusted for age, CD4, VL, baseline ALT, year of sample, duration of HIV infection at the date of sample.
**Further mutually adjusted for all biomarkers.
Marchetti et al. BMC Infectious Diseases 2014, 14:79 Page 6 of 9
http://www.biomedcentral.com/1471-2334/14/79disease in a cohort of HIV-HBV/HCV co-infected pa-
tients. Because of the lack of liver-related clinical events
in our study population we evaluated the risk of liver
disease progression using the elevation of commonly
employed surrogate markers.
In our cohort of HIV-HBV/HCV co-infected patients,
higher TNF-α plasma levels were associated with increased
risk of developing ALT > 200 IU/l (in the unadjusted ana-
lysis only) and Fib-4 > 1.45 (both in the unadjusted and ad-
justed analysis), supporting our a priori hypothesis that a
pro-inflammatory status may induce disease progression in
HIV/hepatitis co-infected patients, possibly as mediator of
hepatic inflammation/angiogenesis.
Nevertheless, to our surprise, higher sCD14 levels
were also independently associated with a decreased risk
of Fib-4 elevation to a value >1.45. Our results appear to
be in disagreement with those obtained in previous ana-
lyses showing a positive association between sCD14 and
viral hepatic disease both in HIV-negative and HIV-
positive individuals [5,9,12]; this may be partly explained
by the different study design, patient populations and
endpoints used to define liver disease progression. In
particular, Redd et al. have recently described an associ-
ation between elevated circulating sCD14 and liver stiff-
ness. However, Redd et al. analysed a very differentpatient population of Ugandans HIV infected individuals
with no viral hepatitis co-infections [13], who may fea-
ture different MT and systemic IA as compared to the
HIV-viral hepatitis co-infected subjects included in our
research.
Interestingly however, our findings are in accordance
with other data reporting an association between lower
circulating sCD14 and increased ALT levels in non-
alcoholic fatty liver disease [16]. As a matter of fact,
amongst its many functions, sCD14 also prevents the
interaction of LPS with phagocyte membrane CD14, thus
hampering the inflammatory response [17]. According to
this alternative model, high sCD14 levels might preserve
liver function by contributing to the down-regulation of
the inflammatory cascade [16,18] which accounts for dis-
ease progression in HIV/hepatitis co-infected patients. As
a possible counterpart to our data, it is intriguing to
speculate that HIV/hepatitis co-infected subjects who are
less likely to progress to liver disease (i.e. Fib-4 >1.45)
maintain high circulating sCD14 that might exert a pro-
tective function against hepatic illness by neutralizing gut-
derived LPS.
An alternative interpretation of our findings is that in
this study liver damage was estimated by means of indir-
ect measures (i.e. ALT or Fib-4 elevations) which are
Table 3 Relative hazards of Fib-4 elevation >1.45 from fitting a Cox regression model
Crude and adjusted relative hazards of developing Fib>1.45
Biomarker Crude RH (95% CI) p-value Adjusted* RH (95% CI) p-value Adjusted** RH (95% CI) p-value
CD8CD38+DR+, %
<=48% 1.0 1.0 1.0
>48% 5.27 (0.59, 47.23) 0.137 4.62 (0.47, 45.35) 0.189 5.34 (0.31, 92.47) 0.250
not measured 2.82 (0.37, 21.58) 0.318 2.88 (0.35, 23.80) 0.327 1.71 (0.19, 15.66) 0.636
IL-6, pg/ml
<=1.1 1.0 1.0 1.0
>1.1 1.67 (0.59, 4.68) 0.333 1.62 (0.52, 5.05) 0.403 1.24 (0.34, 4.58) 0.747
not measured 0.71 (0.18, 2.84) 0.627 0.56 (0.13, 2.46) 0.443 § 0.992
LPS, pg/ml
<=126 1.0 1.0 1.0
>126 0.41 (0.11, 1.60) 0.200 0.36 (0.07, 1.78) 0.211 0.53 (0.08, 3.33) 0.497
not measured 0.53 (0.19, 1.46) 0.217 0.64 (0.21, 1.96) 0.431 0.71 (0.13, 3.89) 0.697
sCD14, mg/ml
<=3.6 1.0 1.0 1.0
>3.6 0.99 (0.36, 2.74) 0.987 0.46 (0.14, 1.53) 0.206 0.20 (0.04, 0.90) 0.036
not measured 0.69 (0.18, 2.61) 0.582 0.33 (0.08, 1.46) 0.145 § 0.992
TNF-alfa, pg/ml
<=2.3 1.0 1.0 1.0
>2.3 8.37 (1.90, 36.87) 0.005 15.17 (2.72, 84.76) 0.002 13.05 (2.43, 70.07) 0.003
not measured 1.70 (0.24, 12.11) 0.596 1.53 (0.17, 13.71) 0.702 0.29 (0.01, 10.81) 0.503
*All models (a separate one for each biomarker) adjusted for age, CD4, VL, Fib, year of sample, duration of HIV infection at the date of sample.
**Further mutually adjusted for all biomarkers; § RH not obtained given small sample size for the parameter.
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disease. In particular, Fib-4 > 1.45 is accepted for F0-F1,
but does not perform well in intermediate stages; how-
ever a Fib-4 value > 3.25 (a more reliable measure for
intermediate fibrosis stages) was observed only in 3 pa-
tients, and, therefore, this more strigent definition of the
endpoint could not be used in this analysis. Conversely,
previous literature reports on HIV/HCV co-infected pa-
tients [5,9], including data from our group [12], de-
scribed in detail the effects of MT in liver disease as
assessed by histology and/or elastography measures.
Given that hepatic stellate cells and Kupffer cells are the
main target through which LPS promotes fibrogenesis
[19], direct measures of liver disease may more faithfully
mirror the effects of MT on hepatic tissues. The use of
ALT/Fib-4 elevations might also explain the discrepan-
cies between our results and the data by Redd et al. who
also identified liver disease by means of transient elasto-
graphy [13]. A further explanation to the difference be-
tween our findings and those by Redd’s is that our study
design is prospective, and might be therefore less prone
to selection bias than a case–control study.
The fact that the results of the analysis using ALT ele-
vation as an endpoint are only in partial agreement with
those found using Fib-4 elevation is obviously of slightconcern. However with 23 and 18 events included in the
analysis, respectively, it is difficult to discern between
genuine differences and discrepancies due to chance cir-
cumstances or lack of power. This is a post-hoc analysis
of a main protocol focusing on HIV-disease progression
endpoint [7], not powered for hepatitis-disease endpoint
and with no current plan to expand the study population
by extracting additional samples from the repository.
Nonetheless, from a more pathogenic standpoint, ALT
levels are a measure of liver inflammation, and Fib-4 re-
flects hepatic fibrosis which does not necessarily occur
at the same time. As a matter of fact, given that inflam-
mation drives fibrosis, heightened ALT levels may occur
prior to Fib-4 increases.
Several other limitations of our study have to be ac-
knowledged. First of all, the design of our study is re-
stricted to HIV-HBV/HCV co-infected patients and
lacks a control group of HCV and/or HBV mono-
infected individuals. Furthermore, the size of our cohort
might not be large enough to allow to draw sure associa-
tions between MT and liver disease progression.
Nevertheless, given the significant clinical burden of
hepatitis co-infection in HIV-positive patients, we be-
lieve that our findings provide a further insight in the
understanding of the contribution of MT in HBV/HCV
Marchetti et al. BMC Infectious Diseases 2014, 14:79 Page 8 of 9
http://www.biomedcentral.com/1471-2334/14/79clinical outcome and may stimulate further research
aimed to specifically investigate the mechanism(s) through
which MTcauses the progression of liver disease.
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